EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSCVAG00000012680
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nuclear Transcription Factor Y Subunit Beta-Like

Ensembl ID : ENSCVAG00000005752
Gene Symbol: LOC107090045
2 Cross references
192 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSCVAG00000020668
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSCVAG00000011000
Gene Symbol: OPRL1
1 Cross references
190 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSCVAG00000009440
Gene Symbol: OPRK1
4 Cross references
196 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSCVAG00000020248
Gene Symbol: OPRD1B
1 Cross references
178 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSCVAG00000001031
Gene Symbol: OXTR
3 Cross references
193 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSCVAG00000005803
Gene Symbol: OXTR
3 Cross references
186 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSCVAG00000019659
Gene Symbol: PAK4
3 Cross references
163 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSCVAG00000018280
Gene Symbol: PTH1R
3 Cross references
198 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSCVAG00000005599
Gene Symbol: PPARD
3 Cross references
392 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSCVAG00000012368
Gene Symbol: PPARG
4 Cross references
389 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).